Pernix Therapeutics Reports First Quarter 2018 Financial Results
May 10, 2018 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today its financial results for the three months...
Pernix Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 10
May 01, 2018 16:05 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results...
Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss
April 23, 2018 11:30 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J, April 23, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has agreed to participate in an...
Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mg
March 27, 2018 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., March 27, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it expects to resume distribution of...
Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 08, 2018 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today financial results for the three and twelve...
Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8
February 22, 2018 16:05 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial...
Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals
February 16, 2018 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced the launch of an authorized generic version...
Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion
February 06, 2018 16:05 ET
|
Pernix Therapeutics Holdings, Inc.
Director John R. Leone Named as the Company’s Lead Independent DirectorAngus Smith Promoted to Senior Vice President, Chief Business Officer and Principal Financial Officer MORRISTOWN, N.J., Feb. ...
Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER
January 29, 2018 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has entered into a settlement...
Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek™ and Silenor®
January 05, 2018 08:30 ET
|
Pernix Therapeutics Holdings, Inc.
Anticipated Cost Savings of $7-$8 Million MORRISTOWN, N.J., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced...